- DKK16.77bn
- DKK16.63bn
- DKK6.04bn
Brief: Ambu Q2 Organic Revenue Growth 7.3%
Brief: Ambu Share Buyback Program Ends
Europe Research Roundup: Equinor, HSBC , RWE
Brief: Ambu Q1 EBIT Ex-Items Slumps To DKK 164 Mln
Ambu dives to the bottom of STOXX on EBIT miss, new guidance
Brief: Ambu Expects Organic Revenue Growth Of 10-13% In 2025/26
Factbox: Who's on Novo Nordisk's board after major shakeup?
European shares close at record high as healthcare outperforms; US shutdown in focus (updated)
Refile: BUZZ-'Overall a relief': TrumpRx price cuts deals boost European pharma stocks
European healthcare stocks surge as US deal with Pfizer reduces some uncertainty (updated)
European healthcare stocks surge as U.S. Pfizer deal reduces some uncertainty
Ambu jumps as long term targets bring relief
Brief: Ambu Extends Long-Term Financial Targets Through 2029/2030
Brief: Us FDA Says Ambu Inc Removes Spur II Resuscitators Due To Blocked Manometer Port
Brief: Ambu Q3 EBIT Before Special Items At DKK 170 Mln
Ambu rises as FDA issues import alerts on rival devices
Brief: Ambu Obtains FDA Clearance For Single-Use Flexible Cysto-Nephroscopy Solution
Ambu drops 10% to bottom of STOXX after Q2 miss
Brief: Ambu Q2 Organic Revenue Growth At 11.7%